Published • loading... • Updated
Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate
- Harbour BioMed announced preclinical data for LET003, its first AI-developed monoclonal antibody targeting ACVR2A/2B using the Hu-mAtrIx™ platform.
- LET003 showed better pharmacokinetics and slower clearance than competitor molecules, allowing for potentially lower or less frequent dosing.
- When combined with semaglutide, LET003 enhanced fat reduction and preserved lean mass significantly.
- LET003 achieved lean mass benefits at lower doses compared to bimagrumab at higher doses, suggesting it may be a best-in-class obesity therapy.
Insights by Ground AI
37 Articles
37 Articles
Harbour posts preclinical data on would-be rival to Eli Lilly’s $1.9B obesity bet - European Biotechnology Magazine
Harbour BioMed has published preclinical obesity data on a potential challenger to Eli Lilly’s bimagrumab discovered using its artificial intelligence-enabled platform. The post Harbour posts preclinical data on would-be rival to Eli Lilly’s $1.9B obesity bet appeared first on European Biotechnology Magazine.
Coverage Details
Total News Sources37
Leaning Left6Leaning Right3Center13Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 27%
C 59%
14%
Factuality
To view factuality data please Upgrade to Premium
